Lexicon Pharmaceuticals (LXRX)
Develops medicines for heart failure, cardiometabolic conditions, and neuropathic pain.
$2.25
Pre-market0.00 (0.00%)
At close$2.25(+2.74%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
−$0.06
Revenue estimate
$2.8M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.09−$0.07$0.01−$0.04−$0.04$0.00−$0.06Pending
Estimate−$0.11−$0.10−$0.08−$0.07−$0.07−$0.04−$0.05−$0.06
Surprise+18.2%+30.0%+112.5%+42.9%+42.9%+93.5%−19.5%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$26.6M$1.3M$28.9M$14.2M$5.5M$21.1M$692.0KPending
Estimate$2.8M$1.3M$5.8M$3.1M$3.1M$9.8M$4.0M$2.8M
Surprise+842.6%−3.4%+396.7%+351.4%+74.8%+115.6%−82.7%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.06 | — | — |
| Aug 2026 | −$0.05 | −$0.06 | −19.5% |
| May 2026 | −$0.04 | $0.00 | +93.5% |
| Mar 2026 | −$0.07 | −$0.04 | +42.9% |
| Nov 2025 | −$0.07 | −$0.04 | +42.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.06 | — | — | $2.8M | — | — | — |
| Aug 6, 2026 | −$0.05 | −$0.06 | −19.5% | $4.0M | $692.0K | −82.7% | −3.7% |
| May 7, 2026 | −$0.04 | $0.00 | +93.5% | $9.8M | $21.1M | +115.6% | +19.1% |
| Mar 5, 2026 | −$0.07 | −$0.04 | +42.9% | $3.1M | $5.5M | +74.8% | +4.3% |
| Nov 6, 2025 | −$0.07 | −$0.04 | +42.9% | $3.1M | $14.2M | +351.4% | −12.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 6, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 6, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Mar 11, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 2, 2023 | |||||||
| Mar 2, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 2, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Jul 30, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 10, 2021 | |||||||
| Oct 29, 2020 | |||||||
| Jul 30, 2020 | |||||||
| Apr 27, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Jul 31, 2019 | |||||||
| May 1, 2019 | |||||||
| Mar 13, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Jul 30, 2018 | |||||||
| May 3, 2018 | |||||||
| Feb 22, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 1, 2017 | |||||||
| May 2, 2017 | |||||||
| Mar 3, 2017 | |||||||
| Nov 1, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 3, 2016 | |||||||
| Mar 1, 2016 | |||||||
| Nov 6, 2015 | |||||||
| Aug 7, 2015 | |||||||